Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.
Pfizer has voluntarily recalled two lots of Chantix 0.5 mg tablets, two lots of Chantix 1 mg tablets, and eight lots of a Chantix kit consisting of 0.5mg/1 mg tablets.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
The FDA said it found an issue with the “size of the treatment effect and clinical relevance” of Ardelyx’s new drug tenapanor without providing additional details.
American health authorities have a dilemma. On one hand, COVID-19 booster shots for immunocompromised patients dramatically increase their immune response. On the other, in many parts of the world only a tiny fraction of the population have received even one dose of any COVID-19 vaccine. So, who should get the vaccines?
The drug is a nucleoside reverse transcriptase translocation inhibitor, with the results presented at the virtual 11th International AIDS Society Conference on HIV Science.
Rivus’ CMAs are designed to overcome these illnesses by activating the body’s natural process of mitochondrial uncoupling.
The recent survival results of Masitinib will help (ALS) patients to live longer. AB Science has successfully established the sweet spot for masitinib in ALS.
Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
The firm would be moving forward to Phase III for the treatment of hypertrophic cardiomyopathy, which is expected to commence before the end of 2021.
PRESS RELEASES
· Supporting the development of its proprietary MIC-Lx Modified Immune Cells technology as a novel approach to reduce lifelong systemic immunosuppression and improve long-term outcomes for transplant recipients · Strengthening MIC-Lx’s regulatory and commercial positioning in Europe
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections